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Abstract
BACKGROUND: Although the exact mechanism leading to preeclampsia is not fully understood, abnormal 
trophoblast invasion contributes to its pathogenesis. Keratins and cadherin are known to play roles in the regulation of 
trophoblast proliferation. However, studies describing the association between keratins, cadherin, and preeclampsia 
are limited.
AIM: The current study was conducted to investigate the association of these proteins with severe preeclampsia in 
Sudanese women.
METHODS: A case–control study was conducted at Madani Maternity Hospital, Sudan. The cases included women 
with severe preeclampsia (n = 56) and healthy pregnant women as controls (n = 56). The assessment of keratin and 
cadherin was performed using immunohistochemical staining. 
RESULTS: There was no significant difference between the two groups in their mean age or parity. We found no 
significant differences in the expression of the markers E-cadherin, N-cadherin, or cytokeratin 18 and 19 in the 
placentas from individuals with preeclampsia versus controls. The number of placentas with severe preeclampsia 
versus controls expressing the E-cadherin, N-cadherin, cytokeratin 18, and cytokeratin 19 markers was 46 (82.1%) 
versus 46 (82.1%) (p = 0.988), 54 (96.4%) versus 48 (85.7%) (p = 0.121), 4 (7.1%) versus 0 (0%) (p = 0.126), and 
11 (19.6%) versus 11 (19.6%) (p = 0.532), respectively. There was also no significant difference in the intensity of 
staining of these four markers (Ecadherin, N-cadherin, and cytokeratin 18 and 19) between severe preeclampsia 
and control placentas. 
CONCLUSION: Together, these results indicate that in this setting, the expression of E-cadherin, N-cadherin, CK18, 
and CK19 is not associated with severe preeclampsia.
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Introduction
Preeclampsia is defined as the occurrence 
of hypertension and proteinuria in the second half of 
pregnancy (i.e., after 20 weeks of gestation) in women who 
had no previous hypertension or proteinuria. It is one of the 
most common medical disorders in pregnancy worldwide, 
with a prevalence of around 3–8% [1], [2]. It is a serious 
pregnancy-related complication that can lead to adverse 
effects for both the mother and the fetus [1], [3]. Whereas 
most cases of preeclampsia are mild and symptomless, 
it may also occur in a severe form, such as hemolysis, 
elevated liver enzymes, low platelets-syndrome, or 
may lead to cerebral manifestations and eclampsia [4]. 
Although the exact pathophysiology and pathogenesis of 
preeclampsia is not completely understood, it is theorized 
that poor/abnormal placentation during early pregnancy 
can lead to placental ischemia and release of vasoactive 
substances, with consequent endothelial activation and 
dysfunction [5].
The proliferation and differentiation processes 
of the human chorionic villous and extra villous 
trophoblast are associated with alterations in the 
expression of keratins and cadherins at various stages 
of pregnancy [6], [7], [8]. Cadherins are glycoproteins 
that are expressed by a variety of tissues. Cadherins 
mediate adhesion and play important roles in the 
formation of tissues during gastrulation [9]. Keratins are 
a family of intermediate filament-forming proteins with 
specific physiochemical properties that contribute to the 
formation of the cytoskeleton; cytokeratin 18 and 19 are 
specifically expressed by epithelial cells, such as placental 
trophoblasts [10]. Cadherins mediate homophilic cell-
cell adhesion and cell-cell recognition [11]. There is a 
limited amount of research regarding the association 
between E-cadherin, N-cadherin, keratin 18, keratin 19, 
and preeclampsia [12], [13], [14], [15], [16]. The current 
study was conducted to investigate the association of 
these proteins with severe preeclampsia in Sudanese 
women.
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Methods
A case–control study was conducted at 
Madani Maternity Hospital, Sudan, during the period 
between September 2017 and December of 2017. 
Madani hospital is a tertiary hospital caring for referred 
women. The cases examined were women with severe 
preeclampsia. Preeclampsia is defined as systolic 
blood pressure ≥140 mmHg or diastolic blood pressure 
≥90 mmHg on two occasions at least 4 h apart after 20 
weeks of gestation in a previously normotensive patient 
and proteinuria ≥0.3 g in a 24-h urine specimen. Severe 
preeclampsia is defined as the occurrence of diastolic 
blood pressure ≥110. Health pregnant women, similar 
in age and similar in other characteristics were used 
as controls. The control women did not have blood 
pressure values >139/89 mmHg or proteinuria. Women 
pregnant with twins, or with previous histories of 
hypertension, renal disease, diabetes, or liver disease 
were excluded from the study. After signing an informed 
consent, both the obstetrics and medical history (age, 
parity, and gestational age) were recorded from each 
woman (cases and controls) using a questionnaire 
that was completed and filed by a trained medical 
officer. Maternal weight and height were measured 
and body mass index was calculated and expressed 
as weight (kg)/height (m)2. The Institutional Ethics 
Committee approved the study protocol, and informed 
consent was obtained from each subject.
Immunohistochemistry
Immediately after delivery, placental samples 
were fixed in 10% neutral buffered formalin solution. 
Samples were cut into to 3–5 mm-thick tissue slices 
and processed in a standard manner for the preparation 
of 4 µ-thick paraffin sections. Sections were de-waxed 
with xylene and hydrated through descending alcohol 
(100%, 90%, 70%, and 50% ethanol and distilled water). 
The sections then were treated for antigens, which were 
retrieved by pre-heated ethylenediaminetetraacetic acid 
pH 9 (Boster biological Technology Co. Ltd., China) in 
a microwaveable chamber, microwaved (at 98°C) for 
20 min. Endogenous peroxidase was blocked using 
0.03% hydrogen peroxide for 5 min. Tissue sections 
were incubated with mouse primary antibody in a 
humid chamber for 45 min using dilutions as follows: 
(K19 clone number RCK108, code: BM3267, 1:50; K18 
clone number DC10, code: AM0094, 1:50; E-cadherin 
clone number ECH-6, code: AM0104, 1:50; N-cadherin 
clone number 6G11, code: AM0170, 1:50) (Gene tech 
company limited, Shanghai, China), and subsequently 
washed with phosphate buffer saline at pH 7.4 (SIGMA, 
USA). Next, sections were incubated with horse-radish 
peroxidase labeled polymers mouse antibody for 
30 min (code: GK500705, Gene tech company limited, 
Shanghai, China). A brown color was developed by 
adding diaminobenzidine tetra hydrochloride (Gene 
tech company limited, Shanghai, China) for 10 min. 
The slides were lightly counterstained using Mayer 
hematoxylin negative control, prepared from the same 
tissues block, but incubated in the phosphate buffer 
solution instead of the primary antibody. Positive control 
sections were added to the process with the placental 
tissue sections in the same run, the staining intensity 
of E-cadherin, CK18 and CK19 in two sites of placenta 
was tested as an internal control and no difference in 
expression was found. Twenty fields were examined 
for each section by an expert pathologist blinded to 
the tissue identity and scored for intensity and location 
of staining as follows: Level of staining assessed as 
0 = no staining, 1 = low staining, 2 = medium staining, 
and 3 = intense staining. All sections were stained in 
the same batch to control for inter-batch variation.
Data analysis
Data were entered into the computer using 
SPSS version 20.0 (SPSS Inc., Chicago, IL, USA) 
for Windows. Continuous and categorized data 
were compared between the two groups (severe 
preeclampsia and healthy controls) using Student’s 
t-test and Chi-square test, respectively. p < 0.05 was 
considered significant.
Results
Fifty-six placentas were investigated in each 
arm of the study. There were no significant differences 
in the mean (SD) age, parity, or hemoglobin levels 
between the two groups. Compared to controls, women 
with severe preeclampsia had significantly lower 
gestational age and birth weights (Table 1).
Table 1: Mean (SD) of the clinical and obstetrics characteristics 
of women with severe preeclampsia and healthy controls
Variables Severe preeclampsia (n=56) Controls (n=56) p-value
Age, years 28.9 (5.2) 28.5 (4.9) 0.7310
Parity 3.1 (1.9) 2.8 (1.6) 0.502
Gestational age, weeks 36.2 (2.9) 37.8 (0.9) <0.001
Body mass index, kg/m2 24.6 (2.1) 24.4 (2.3) 0.677
Hemoglobin, g/dl 10.2 (1.3) 9.9 (1.8) 0.284
Birth weight, g 2560 (451) 3019 (321) <0.001
There were no significant differences in the 
absolute expression of these markers. Of the placentas 
tested from severe preeclampsia and control patients, 
there were 46 (82.1%) versus 46 (82.1%) (p = 0.988), 54 
(96.4%) versus 48 (85.7%) (p = 0.121), 4 (7.1%) versus 
0 (0%) (p = 0.126), and 11 (19.6%) versus 11 (19.6%) 
(p = 0.532) that expressed E-cadherin, N-cadherin, and 
cytokeratin 18 and 19, respectively.
There was no significant difference in the 
intensity of staining of the four markers (E-cadherin, 
N-cadherin, and cytokeratin 18 and 19) between the 
placentas of severe preeclampsia and controls (Table 2). 
Only one placenta from a severe preeclampsia patient 
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Figure 1: Photographs of immunohistochemical staining. (a) Keratin18 expression was negative in normotensive placentae immunohistochemistry 
(IHC) (×40). (b) Keratin18 expression was strong in preeclampsia placentae IHC (×40). (c) Keratin19 expression was negative in women 
placenta with preeclampsia IHC (×40). (d) Keratin19 expression was strong in normotensive placentae IHC (×40). (e) E-cadherin was negative 
in normotensive placentae IHC (×40). (f) E-cadherin was weak in in women placenta with preeclampsia IHC (×40). (g) N-cadherin negative in 
women placenta with preeclampsia IHC (×40). (h) N-cadherin was weak in normotensive placentae IHC (×40)
a b
c d
e f
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expressed the four markers (E-cadherin, N-cadherin, 
and cytokeratin 18 and 19), p = 0.500. Both E-cadherin 
and N-cadherin were expressed in 43 (76.8%) versus 
40 (71.4%), p = 0.333 of the placentas of the severe 
preeclampsia and controls, respectively. Only 2 (3.2%) 
versus 0 (0%), p = 0.248 of placentas of severe 
preeclampsia cases expressed cytokeratin 18 and 19 
(Figure 1).
Discussion
The main findings of the current study indicate 
that there were no significant differences in the 
expression of keratin 19, keratin 18, and N-cadherin 
in placentas from women with severe preeclampsia, 
compared to placentas from healthy controls. 
Interestingly, Li et al. reported no significant differences 
in the expression of N-cadherin between preeclampsia 
and control cases. However, they did report a significant 
increase in the expression of E-cadherin, cytokeratin 
18, and cytokeratin 19 in preeclampsia placentas, 
compared to normotensive pregnancies [12]. Moreover, 
Du et al. reported that the expression of E-cadherin is 
higher, whereas the expression of N-cadherin is lower 
in the placentas of preeclamptic women, compared to 
the placentas of the healthy controls [17].
A significant increase in the expression and 
significantly higher level of cytokeratin 18 has recently 
been recently in placental samples from women with 
preeclampsia compared to controls [13]. Likewise, 
an upregulation of E-cadherin expression has been 
reported in preeclampsia patients [16]. Tempfe et al. 
reported a significant association between cytokeratin 
B - Clinical Sciences Gynecology and Obstetrics
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19 and preeclampsia, especially the severe form of 
preeclampsia [14]. On the other hand, keratins 18 and 
19 have been reported to be downregulated in villous 
trophoblasts in preeclampsia [15].
It is worth mentioning that E-cadherin and 
cytokeratin 18 have been proposed to be markers 
for apoptosis, which is a feature of preeclampsia that 
contributes to placental malfunctioning and impairs 
maternal-fetal transfer functions [18]. Al-Nasiry et al. 
reported that trophoblast fusion is associated with a 
downregulation of E-cadherin and defective placentation 
in preeclampsia [19].
The attachment of cells to each other is 
mediated by interactions between homophilic cadherin 
molecules that include Epithelial (E) E-cadherin and 
Neural (N) N-cadherin; these cadherin molecules are 
linked to different cytoskeletal elements, for example, 
keratins 19 and 18 [20]. N-cadherin is associated 
with the epithelial–mesenchymal transition and is 
imperative for well-coordinated and coherently layered 
villous cytotrophoblasts, which change into extravillous, 
migratory and invasive trophoblasts [8]. E-cadherin is 
essential for embryonic development as it is expressed 
in epithelial cells and the localization of cadherins is 
highly relevant to the morphology of trophoblasts at 
different stages of placental development and villous 
differentiation [21].
Conclusion
Caution should be taken when comparing 
these findings with later studies because, although 
we found that the correlations were not statistically 
significant, there were clear differences within the set 
of affected women, and the sensitivity of the detection 
methods, and the sampling area in the placenta, is 
very important for determining the expression of such 
markers.
Limitations of the study
The assessments of keratin and cadherin were 
performed only through immunohistochemical staining.
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